EDITGENE CO., LTD

17800 Castleton St. Ste 665. City of Industry. CA 91748

info@editxor.com

+1-833-226-3234 (USA Toll-free)
+1-224-345-1927 (USA)
+86-19120102676 (Intl)


Technical Support
Support Center
Beijing Time: Monday to Friday, 8:00 AM - 6:00 PM
Toll-Free (USA): +833-226-3234
Direct Line (USA): +1-224-345-1927
Email: techsupport@editxor.com
After-Hours Support
Beijing Time: Monday to Sunday, 8:00AM - 6:00 PM
International Line: +86-19120102676
Email: info@editxor.com
Whatsapp
Connect with us instantly on WhatsApp for quick inquiries and real-time support.
Office WhatsApp
Facebook Messenger
Reach out to us on Facebook Messenger for personalized assistance and detailed information.
Linkedin
Engage with us on LinkedIn for professional inquiries, the latest blogs, discoveries, and updates on our innovative work.
FAQ
What are the potential applications of iPSCs in clinical practice?
iPSCs have broad clinical potential, including applications in cell therapy (e.g., for diabetes or heart disease treatment), tissue engineering (e.g., development of artificial skin or liver tissue), and personalized drug screening (e.g., selecting optimal treatments based on a patient’s specific cellular response). These applications may transform treatment methods, offering more effective and personalized medical services.
What is the core principle of gene knock-in technology?
Gene knock-in technology involves inserting an exogenous gene sequence into a specific location within the genome for gene function studies or disease treatment. Edigene utilizes advanced gene editing tools, such as the CRISPR/Cas9 system, to guide nucleases to cut the target DNA, and employs homology-directed repair or non-homologous end joining to accurately insert the gene at the desired location, achieving efficient and precise gene knock-in.
What role does gene knock-in play in drug development?
Gene knock-in plays a crucial role in drug development. It is used in target validation by introducing specific genes into cell lines or animal models to confirm drug target efficacy. It also aids in establishing disease models, testing drug efficacy and safety in these models, and supporting drug screening through high-throughput screening in knock-in cell lines to identify potential drug candidates. Additionally, gene knock-in helps uncover drug mechanisms, optimize drug structure, and improve dosing strategies, expediting drug development while enhancing efficacy and safety.
Why choose EDITGENE, and what are EDITGENE’s main advantages in gene knock-in technology?
EDITGENE’s advantages in gene knock-in technology include:
Guaranteed results: With 10 years of CRISPR gene editing experience and a team of PhDs from world-renowned institutions offering one-on-one support.
High precision: EDITGENE’s optimized tools reduce off-target effects, enhancing editing accuracy.
High efficiency: EDITGENE’s technology platform improves knock-in success rates, accelerating experimental progress.
Customized service: Tailored knock-in solutions to meet specific research or therapeutic goals.
What is the difference between a stable cell line and a transient cell line?
The main difference lies in the duration and stability of gene expression:
Transient cell line – The target gene is expressed temporarily in cells, typically lasting hours to days, and is suitable for short-term experiments.
Stable cell line – The target gene is stably integrated into the cell genome, allowing long-term expression, suitable for extended research and production.
Why conduct gene overexpression?
Gene overexpression aids in studying the function of specific genes, revealing their role within the organism. It is also commonly used in drug screening, vaccine development, and protein production. For example, by overexpressing a therapeutic protein, researchers can evaluate its efficacy in disease models.
What is gene overexpression?
Gene overexpression refers to using various techniques to significantly increase the expression level of a specific gene in cells or organisms. This is often achieved by introducing additional gene copies or using strong promoters to drive gene expression.
How do I choose suitable cells for library screening?
Cell selection can follow these principles:
1.It should align with the research objectives.
2.The genes targeted by the sgRNA library should correspond to the cell's lineage.
3.The cells should be capable of stable passaging.
4.The transfection efficiency should be high.
5.Avoid primary cells whenever possible. Primary cells cannot be stably passaged and may experience significant cell death during the library screening process, which can hinder experiment completion. If primary cells must be used for library screening, mitigating this risk can be achieved by lowering cell coverage and choosing a library with fewer gRNAs to minimize the cell pool size and shorten the experimental duration.
1.It should align with the research objectives.
2.The genes targeted by the sgRNA library should correspond to the cell's lineage.
3.The cells should be capable of stable passaging.
4.The transfection efficiency should be high.
5.Avoid primary cells whenever possible. Primary cells cannot be stably passaged and may experience significant cell death during the library screening process, which can hinder experiment completion. If primary cells must be used for library screening, mitigating this risk can be achieved by lowering cell coverage and choosing a library with fewer gRNAs to minimize the cell pool size and shorten the experimental duration.
What unique advantages does EDITGENE offer for monoclonal screening services?
EDITGENE utilizes industry-leading 3D single-cell printing technology, which enables precise isolation and positioning of individual cells, significantly increasing the success rate and efficiency of monoclonal screening. This technology is widely applied in biomedicine research, antibody development, drug screening, and therapeutic selection, showcasing broad application prospects in cell research.
What is monoclonal screening, and why is it so important in gene editing research?
Monoclonal screening is the process of isolating a single clone from a mixed pool of cells and expanding that clone into a cell line. Monoclonal screening ensures that the cell lines used originate from a single cell, guaranteeing a high degree of genetic background consistency. After cells are gene-edited or genetically modified, the genetic background differences among the cells in the initial cell pool can be significant, making subsequent experimental results inaccurate. By using monoclonal screening, researchers can obtain cell populations with consistent genetic backgrounds and stable gene edits, allowing for stable and accurate monitoring of phenotypic changes.
How do I choose between a whole-genome or subgenomic CRISPR library?
CRISPR libraries can be divided into whole-genome libraries and subgenomic libraries. If the goal is to perform screenings across the entire genome, a whole-genome library is the best choice. Such libraries typically contain sgRNAs targeting the entire genome. If the research focus is specific, such as targeting only particular gene families or specific signaling pathways, a subgenomic library can be chosen to reduce unnecessary screening workload and costs.
What is the difference between induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs)?
Both iPSCs and embryonic stem cells (ESCs) have pluripotency, but iPSCs are obtained by reprogramming the somatic cells, while ESCs come from early embryos. IPSC does not involve the use of embryos and does not violate ethical requirements, so it can also avoid immune rejection issues in scientific research. Therefore, iPSC is considered to be a preferred choice.
What are the differences between Cas9, Cas12, and Cas13?
The main differences among Cas9, Cas12, and Cas13 lie in their action mechanisms:
· Cas12 is activated to cleave ssDNA trans-cleaving after binding with guide RNA and target DNA.
· Cas13 is activated to cleave ssRNA trans-cleaving after binding with guide RNA and target RNA.
· Cas9 has not been reported to exhibit trans-cleaving activity.
· Cas12 is activated to cleave ssDNA trans-cleaving after binding with guide RNA and target DNA.
· Cas13 is activated to cleave ssRNA trans-cleaving after binding with guide RNA and target RNA.
· Cas9 has not been reported to exhibit trans-cleaving activity.
Can both dsDNA and ssDNA targets activate the trans-cleaving activity of Cas12a? Which has higher efficiency?
Both double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) targets can activate the trans-cleaving activity (also known as collateral cleavage) of Cas12a, similar to Cas12b. However, the efficiency differs: ssDNA targets activate Cas12b trans-cleaving activity more efficiently than dsDNA targets, while dsDNA targets activate Cas12a trans-cleaving activity more efficiently than ssDNA targets.
How long can CRISPR-related reagents and Cas proteins be stored?
CRISPR detection reagents:
1.The RPA isothermal amplification kit can be stored at -20°C for long-term storage.
2.Target plasmids can be stored at -20°C for long-term use.
3.Cas proteins are sensitive to repeated freeze-thaw cycles; it is recommended to aliquot into multiple tubes and store at -80°C, retrieving them as needed for experiments. For short-term use, they can be stored at -20°C.
4.crRNA is prone to degradation and should be stored at -80°C if not used in the short term.
5. Probes, being double-stranded DNA, are relatively stable and can be stored at -20°C.
1.The RPA isothermal amplification kit can be stored at -20°C for long-term storage.
2.Target plasmids can be stored at -20°C for long-term use.
3.Cas proteins are sensitive to repeated freeze-thaw cycles; it is recommended to aliquot into multiple tubes and store at -80°C, retrieving them as needed for experiments. For short-term use, they can be stored at -20°C.
4.crRNA is prone to degradation and should be stored at -80°C if not used in the short term.
5. Probes, being double-stranded DNA, are relatively stable and can be stored at -20°C.